Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

Oxford Bio’s recently-appointed chief executive, Dr Frank Mathias, said buying ABL would contribute to the company’s strategy to transition to a pure-play CDMO focusing on the cell and gene ...

Figure 2: BCR-ABL contributes to differentiation arrest ... It seems likely that microarray gene-expression profiling will continue to identify many candidate genes. The next challenge is ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.

CML diagnoses are confirmed if the Philadelphia chromosome or BCR-ABL gene is detected in bone marrow cells. The course of treatment depends on which phase of the disease a person is in ...

Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...

Discovery of the Philadelphia (Ph) chromosome in 1960 paved the way to identification of BCR/ABL as the principal genetic ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...